Justifiable Lack Of Excitement [Seeking Alpha]
SELLAS Life Sciences Group, Inc. (SLS)
Last sellas life sciences group, inc. earnings: 11/14 04:41 pm
Check Earnings Report
US:NYSE Investor Relations:
sellaslifesciences.com/investors/overview/default.aspx
Company Research
Source: Seeking Alpha
Summary Investment Thesis The company is undercapitalized. There is no way for the company to bring their products to approval and production without further massive dilution of the shareholders. Even under optimistic scenarios, the revenues are still many years away. The market is not excited about the products and the stock. That is likely to continue. Every significant rally in the stock should be sold. Brief Overview SELLAS Life Sciences focuses on the development of immunotherapies for a range of cancers. The lead product, GALINPEPIMUT-S, is about to enter phase 3 clinical trials for patients with Acute Myeloid Leukemia ( AML ) and Malignant Plural Mesothelioma ( MPM ). Another product, NEUVAX™ (NELIPEPIMUT-S), is undergoing phase 2 clinical studies in combination with TRASTUZUMAB for certain types of breast cancer patients. An update on the study will be presented in October 2018 at an upcoming European Society for Medical Oncology meeting. Other products (GA
Show less
Read more
Impact Snapshot
Event Time:
SLS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLS alerts
High impacting SELLAS Life Sciences Group, Inc. news events
Weekly update
A roundup of the hottest topics
SLS
News
- SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate UpdateGlobeNewswire
- GenFleet and BeiGene Enter into Trial Collaboration for a Potentially First-in-class Combination Therapy to Initiate Phase Ib/II Study of GFH009 (CDK9 inhibitor) and BRUKINSA® (zanubrutinib) Treating Diffuse Large B Cell LymphomaPR Newswire
- SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study [Yahoo! Finance]Yahoo! Finance
- SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL StudyGlobeNewswire
SLS
Sec Filings
- 3/28/24 - Form S-3
- 3/28/24 - Form S-3
- 3/28/24 - Form 8-K
- SLS's page on the SEC website